Αποτελέσματα Αναζήτησης
FDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age. The FDA amended the emergency use authorizations (EUAs) of the updated (bivalent) Moderna and...
- Novavax COVID-19 Vaccine, Adjuvanted | FDA - U.S. Food and Drug ...
The Novavax COVID-19 Vaccine, Adjuvanted, a monovalent...
- FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in ...
Today, the U.S. Food and Drug Administration authorized the...
- Novavax COVID-19 Vaccine, Adjuvanted | FDA - U.S. Food and Drug ...
15 Φεβ 2023 · The phase 1 dose-finding study and ongoing phase 2–3 safety, immunogenicity, and efficacy trial investigated BNT162b2 in healthy children 6 months to 11 years of age. Safety and immunogenicity...
9 Νοε 2021 · A Covid-19 vaccination regimen consisting of two 10-μg doses of BNT162b2 administered 21 days apart was found to be safe, immunogenic, and efficacious in children 5 to 11 years of age....
30 Δεκ 2021 · On October 29, 2021, the Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 (BNT162b2) mRNA vaccine to expand its use to children aged 5–11 years, administered as 2 doses (10 μg, 0.2mL each) 3 weeks apart (1).
9 Σεπ 2022 · On June 17, 2022, the Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for mRNA COVID-19 vaccines to include children aged 6 months–4 years for receipt of BNT162b2 (Pfizer-BioNTech) (administered as 3 doses, 3 μ g [0.2 mL] each) and children aged 6 months–5 years for receipt of mRNA-1273 (Moderna) (administered as...
Our near–real-time monitoring results for 20 prespecified health outcomes in the pediatric population provide reassuring real-world evidence of the safety of the BNT162b2 COVID-19 vaccine in children and adolescents.
29 Οκτ 2021 · Today, the U.S. Food and Drug Administration authorized the emergency use of the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include children 5 through 11 years of...
